Drug search by name

AccessPak for HIV PEP Expanded with Kaletra and Hepatitis B

Result of checking the interaction of drug AccessPak for HIV PEP Expanded with Kaletra and disease Hepatitis B for safety when used together.

Check result:

AccessPak for HIV PEP Expanded with Kaletra <> Hepatitis B

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of other products containing these agents. It is recommended that patients with HIV-1 be tested for the presence of chronic hepatitis B virus (HBV) infection before or when initiating antiretroviral therapy. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue FTC and or TDF, or other products containing these drugs. If appropriate, anti-hepatitis B therapy may be warranted according to clinical practices, especially in patients with advanced liver disease or cirrhosis, since post-treatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.

AccessPak for HIV PEP Expanded with Kaletra

Generic Name: emtricitabine / lopinavir / ritonavir / tenofovir

Brand Name: AccessPak for HIV PEP Expanded with Kaletra

Synonyms: n.a.

What is AccessPak for HIV PEP Expanded with Kaletra?